▲ S&P 500 +---% | ▲ Stock Advisor +---% Join The Motley Fool

Accessibility Log In Help

Daily Stock Gainers Daily Stock Losers Most Active Stocks

Daily Stock Gainers Daily Stock Losers Most Active Stocks

Eileen Rojas

er529

Eileen has been a Foolish Contributor since 2013 focusing on consumer goods and healthcare. She has a Master's and Bachelor's degree in Accounting from Florida International University.

Recent Articles by Eileen Rojas

Apr 4, 2014 by Eileen Rojas

Abercrombie’s Hollister Brand Zooms Into Fast-Fashion Segment

With lagging sales, Abercrombie is re-branding Hollister to tap into the success achieved by its fast-fashion competitors.

Mar 26, 2014 by Eileen Rojas

Safeway Is Latest Buyout Target as Grocer Consolidation Continues

Safeway may soon join forces with Albertsons, as private equity owner Cerberus Capital Management continues to buy up grocery stores.

Mar 25, 2014 by Eileen Rojas

Will Spring Bring a Shower of Sales for These Retailers?

The harsh winter weather had a negative impact on some retailers during February, while some managed to come out ahead.

Mar 20, 2014 by Eileen Rojas

Staples' Increased Focus on E-commerce Means Fewer Stores

Office supply retailer Staples will close several of its locations, as its e-commerce site reports higher growth.

Mar 19, 2014 by Eileen Rojas

There’s More to Costco’s Story Than Its Latest Earnings Show

Costco missed EPS estimates for the second quarter, but the company’s solid operating strategy should maintain long-term profitability.

Mar 15, 2014 by Eileen Rojas

J. Crew Ponders a Possible IPO

Will J. Crew become the next hot retail stock?

Mar 14, 2014 by Eileen Rojas

What's Next for Rockwell Medical?

Dialysis treatment provider Rockwell Medical’s sales have been rising, but is the stock a good purchase?

Mar 3, 2014 by Eileen Rojas

Is Merck Slimming Down?

Like some of its competitors, Merck is looking to streamline its business and put greater focus on its core products.

Feb 25, 2014 by Eileen Rojas

After Cangrelor, The Medicines Company Gets Priority Review for New Drug

After its anti-clotting agent Cangrelor was rejected by an FDA committee, The Medicines Company sets its sights on getting approval for skin infection drug oritavancin.

Feb 18, 2014 by Eileen Rojas

Can a New Indication for Lyrica Help Results at Pfizer?

A new study showed the efficacy of using Lyrica to treat Restless Legs Syndrome over another treatment -- Boehringer Ingelheim’s Mirapex.

Feb 18, 2014 by Eileen Rojas

What to Look for in Community Health Systems’ Fourth Quarter Report

As Community Health Systems reports fiscal 2013 fourth quarter earnings later today, investors should look for updates on the following key areas.

Feb 13, 2014 by Eileen Rojas

AstraZeneca’s Alzheimer’s Drug Advances: Now What?

AstraZeneca reported disappointing fourth quarter revenues but showed progress with an Alzheimer's therapy the company has under development.

Feb 11, 2014 by Eileen Rojas

Looking Ahead at LifePoint Hospitals’ Fourth Quarter Earnings

Some key areas for investors to consider when acute care hospital operator LifePoint Hospitals releases its fourth quarter earnings on Friday.

Feb 7, 2014 by Eileen Rojas

Will These Two Drugs Turn Around Losses at Pfizer?

Pfizer is working on an experimental drug for breast cancer and expanding use of a pneumonia vaccine to offset losses from patent expirations.

Jan 27, 2014 by Eileen Rojas

Medtronic’s Renal Denervation System Stumbles

The latest trial for Medtronic’s renal denervation system, a procedure used to treat drug-resistant blood pressure, was negatively impacted by the placebo effect.

Jan 23, 2014 by Eileen Rojas

Merck Gets Good News On New Heart Attack Therapy

Merck’s new heart attack therapy, vorapaxar, gets favorable FDA review, as a recent study shows it reduces the risk of cardiovascular death.

Jan 20, 2014 by Eileen Rojas

Could a Medical Device Be Google’s Next Major Project?

Google scheduled a meet-and-greet with the FDA, raising speculation that an eye device with biosensors may be on the drawing board.

Jan 19, 2014 by Eileen Rojas

FDA Okays First Two-Drug Treatment For Melanoma

GlaxoSmithKline receives FDA approval on a novel treatment combination for late-stage melanoma.

Jan 18, 2014 by Eileen Rojas

IPO Costs Drag Down Results at The Container Store

As The Container Store deals with the costs of its recent IPO, cost containment will be key for future growth.

Jan 15, 2014 by Eileen Rojas

What Does This New Diabetes Drug Mean for AstraZeneca and Bristol-Myers Squibb?

Bristol-Myers Squibb and AstraZeneca received FDA approval for their jointly developed diabetes drug Farxiga, but several post-market studies must be conducted.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services